贯众提取液对革兰氏阳性球菌的抑菌作用

目的：了解贯众(Dryopteris crossirhizomz)不同提取液对革兰氏阳性球菌的抑菌作用。方法：分别用水以及3种不同pH值的70％乙醇为溶媒提取贯众干品以制备贯众提取液，利用打孔法和试管稀释法测定提取液对13种微生物的抑制效果。结果：每1ml含生药1g的贯众醇提液、水提液对革兰氏阳性菌有较强的抑制作用，尤其是革兰氏阳性球菌如金黄色葡萄球菌和甲型溶血性链球菌等。对革兰氏阴性菌和真菌的抑制作用较弱，但对普通变形杆菌则有较强的抑制作用。不同pH值的抽提溶剂对药物的有效抑菌成份的提出效果不同，抽提溶剂pH越小，有效成份的提出效果越好。结论：贯众醇提液、水提液对革兰氏阳性菌有较强的抑制作用，尤其是对革兰氏阳性球菌，而对革兰氏阴性菌和真菌的抑制作用则较弱。贯众的抗菌成份易溶于水，抽提效果随pH减小而增加。     

Ivermectin for the chemotherapy of bancroftian filariasis: a meta-analysis of the effect of single treatment

Summary The efficacy and safety of ivermectin in the treatment of filariasis due to Wuchereria bancrofti was assessed by a meta-analysis of the results from 15 published clinical trials. Seven hundred and forty-eight microfilaraemic patients were enrolled in 7 dose-finding and 8 comparative studies. Administered as a single dose, ivermectin induced nearly complete clearance of microfilariae from the blood from the first day to 30 days post-treatment, followed by gradual recurrence of microfilaraemia and increase in its intensity. Higher doses of ivermectin showed greater clearance effects and maintained lower microfilaraemia levels for a longer time. The adverse reactions caused by the drug were flu-like, transient, generally mild and well tolerated by patients. The frequency and intensity of adverse reactions were strongly associated with pretreatment microfilaria counts in the blood, but independent of dose. The findings of the meta-analysis suggest that ivermectin given at a single annual dose of 200 μg/kg body weight or higher, whether or not in combination with DEC, has great potential for therapeutic strategies to control bancroftian filariasis.     

经皮射频消融与手术切除治疗直径≤ 3 cm原发性小肝癌的疗效分析

目的 分析经皮射频消融（PRFA）与手术切除治疗直径≤3 cm原发性小肝癌的疗效。方法 选取2015年1月—2017年6月兰州市第二人民医院收治的原发性小肝癌患者78例。将36例接受PRFA治疗的患者作为观察组,另外42例行手术切除的患者作为对照组。采用全自动生化分析仪检测血清谷草转氨酶（AST）、谷丙转氨酶（ALT）、总胆红素（TBIL）水平,电化学发光全自动免疫分析仪检测血清甲胎蛋白（AFP）水平。结果 观察组手术时间、术中出血量、住院时间均少于对照组（P <0.05）;观察组治疗前后AST、ALT、TBIL、AFP的差值均高于对照组组（P <0.05）。两组术后并发症比较,差异无统计学意义（P>0.05）;两组治疗后1、2、3、5年的生存率和复发率比较,差异均无统计学意义（P>0.05）。结论 与手术切除比较,PRFA治疗直径≤3 cm原发性小肝癌可缩短手术时间,减少术中出血量,促进肝功能恢复,但两者术后并发症发生率、生存率和复发率接近。     

改良尿道板重建卷管尿道成形术与尿道板纵切卷管尿道成形术治疗儿童尿道下裂的疗效对比

目的 比较改良尿道板重建卷管尿道成形术（又称Koyanagi术）与尿道板纵切卷管尿道成形术（TIP）在儿童尿道下裂中的临床疗效。方法 回顾性分析2018年1月—2021年10月甘肃省妇幼保健院收治的104例尿道下裂患儿的临床资料,其中53例患儿行改良Koyanagi术（研究组）,51例患儿行TIP（对照组）。两组患儿术后均随访12个月。比较两组手术时间、术中出血量、术后疼痛及排尿功能、手术成功情况,对比两组术后并发症发生情况。结果 两组手术时间、术中出血量比较,差异均无统计学意义（P >0.05）。两组患儿术后4、12、24和48 h的FLACC评分比较,采用重复测量设计的方差分析,结果 ①不同时间点FLACC评分差异有统计学意义（F =10.871,P =0.000）;②研究组与对照组FLACC评分差异无统计学意义（F =1.849,P =0.157）;③研究组与对照组FLACC评分变化趋势差异无统计学意义（F =2.516,P =0.085）。两组患儿术后12个月的最大尿流率、平均尿流率、排尿量、尿流时间、手术成功率比较,差异均无统计学意义（P >0.05）。研究组术后总并发症发生率低于对照组（P <0.05）。结论 改良Koyanagi术与TIP治疗儿童尿道下裂疗效相近,均可获得满意效果,但改良Koyanagi术在降低术后并发症方面具有优势。     

Anti-conflict efficacy of buspirone following acute versus chronic treatment

In many animal studies, acute treatment with the novel anxiolytic agent buspirone exhibits only minimal anxiolytic efficacy (i.e., increases in punished responding) when compared to benzodiazepines and barbiturates. The present studies examined the effects of acute pre-test challenges with buspirone in subjects receiving chronic post-test buspirone or saline treatments. Chronic post-test treatment with buspirone (4 mg/kg/day for 4 weeks, followed by 8 mg/kg/day for 12 weeks) did not significantly affect CSD behavior. Consistent with previous reports, acute pre-test administration of buspirone (0.125–2 mg/kg, IP) to subjects receiving chronic post-test saline treatment resulted in only a modest anti-conflict effect in the CSD paradigm (approximately ten shocks over control). In contrast, subjects chronically treated with buspirone exhibited a dramatically greater anti-conflict effect following acute challenge with buspirone (up to 40 shocks over control). These data are consistent with the hypothesis that the full anxiolytic efficacy of buspirone requires repeated administration.     

A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract

Fifty-eight patients with well-documented history of seasonal rhinoconjunctivitis caused by grass pollens were allocated randomly on a double-blind basis to receive either sublingual therapy with a solution of purified, standardized allergen preparation (Stallergenes) or a matched placebo for 17 weeks. The assessment of the effect of oral immunotherapy, done with drops of five-grass allergen extract, was on the clinical symptoms and on the medication score of the authorized rescue treatments. The actively treated patients had significantly (P<0.05 to P<0.01) fewer symptoms of rhinitis (sneezing and rhinorrhea) and of conjunctivitis (redness and tears) during the pollen season than the placebo group. Consumption of nasal solution of sodium cromoglycate and of betamethasone and dexchlorpheniramine was significantly less in the desensitized group (P<0.01). Side-effects were negligible. This study concludes that perlingual immunotherapy with grass pollen extract in grass-pollen-sensitive seasonal hay fever and conjunctivitis patients is effective, easy to perform, inexpensive, and safe.     

床边屏蔽辅助板的设计

目的　制作具有升降调节功能的床边屏蔽辅助板 ,防范等高散射线 ,增加近台操作的安全防护系数 ,使腹部以下透射剂量率下降至最小程度。方法　制作带有内铅层的空腔竖立直板 ,内层铅板可在竖立直板空腔内上 下移动 ,满足不同的床边屏蔽高度。结果　屏蔽床边位屏蔽辐射实验测定值与市防站的实际测定值分别为 2 .5 0× 10 8μGy/h和 2 .5 8× 10 8μGy/h,符合最优化设计及国家标准要求。结论　本研究研制的床边屏蔽辅助板具有较高的临床实用价值     

Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double-blind, placebo-controlled study

BACKGROUND: The allergological relevance of Ambrosia in Europe is growing but the efficacy of the injective immunotherapy for this allergen has been documented only in Northern America. OBJECTIVE: We sought to study the safety and efficacy of injective immunotherapy in European patients sensitized to Ambrosia artemisiifolia. METHODS: Thirty-two patients (18 M/14 F, mean age 36.78, range 23-60 years) suffering from rhinoconjunctivitis and/or asthma and sensitized to Ambrosia were enrolled and randomized in a double-blind, placebo-controlled (DBPC) study lasting 1 year. A maintenance dose corresponding to 7.2 microg of Amb a 1 was administered at 4-week intervals after the build-up. During the second and the third year, all patients were under active therapy in an open fashion. Symptom and medication scores, skin reactivity to Ambrosia (parallel line biological assay), and pollen counts were assessed throughout the trial. RESULTS: Twenty-three patients completed the trial. No severe adverse event was observed. During the DBPC phase, actively treated patients showed an improvement in asthmatic symptoms (P=0.02) and drug (P=0.0068) scores days with asthmatic symptoms (P=0.003), days with rhinitis symptoms (P=0.05), and days with intake of drugs (P=0.0058), as compared to before therapy. No improvement for any of these parameters was detected in the placebo group. Moreover, the number of days with rhinitis and asthma was significantly higher in the placebo as compared to the active group (P=0.048 and P<0.0001, respectively). Patients who switched from placebo to active therapy improved in rhinoconjunctivitis, asthma, and drug intake. The skin reactivity decreased significantly (12.2-fold, P=0.0001) in the active group whereas a slight increase (1.07-fold, P=0.87) was observed in the placebo group after the DBPC phase. After switching to active therapy, patients previously under placebo showed a significant decrease of this parameter (4.78-fold, P=0.002). CONCLUSION: Injective immunotherapy is safe and clinically effective in European patients sensitized to Ambrosia.     

解剖钢板结合连续被动运动功能锻炼治疗胫骨平台骨折

目的 评价解剖钢板结合连续被动运动(CPM)功能锻炼在治疗胫骨平台骨折中的应用价值.方法 2003年5月至2005年10月本院34例胫骨平台骨折行解剖复位、解剖钢板内固定并在术后进行CPM功能锻炼.结果 术后对患者行X线检查示骨折实现解剖复位或接近解剖复位.23例患者经5～30个月随访骨折均愈合,无植骨坏死发生.CPM功能锻炼后运动功能恢复优良率为82.6%(19/23).结论 采用关节面的解剖复位、解剖钢板及牢固固定后配合术后CPM功能锻炼对于胫骨平台骨折有很好的疗效.